Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2 |Cadherin-17 
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-2 R beta & IL-2 R alpha & IL-2 R gamma

IL-2 R beta & IL-2 R alpha & IL-2 R gamma

Brief Information

Name:Interleukin-2
Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:35
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
ILG-H52W9 Human Human IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, His Tag&Twin Strep Tag (MALS verified)
ILG-H52W9-sds
ILG-H82W9 Human Biotinylated Human IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, His,Avitag™&Twin Strep Tag (MALS verified)
ILG-H82W9-sds
ILG-R5223 Rat Rat IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, His Tag&Twin-Strep Tag (MALS verified)
ILG-R5223-sds
ILG-C82F6 Cynomolgus Biotinylated Cynomolgus IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, Fc,Avitag™&Fc,Avitag™ (MALS verified)
ILG-C82F6-sds
ILG-M5253 Mouse Mouse IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, Fc Tag&Fc Tag
ILG-M5253-sds
ILG-H82F4 Human Biotinylated Human IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, Fc,Avitag™&Fc,Avitag™ (MALS verified)
ILG-H82F4-sds
ILG-H5257 Human Human IL-2 R beta&IL-2 R alpha&IL-2 R gamma Protein, Fc Tag&Fc Tag (MALS verified)
ILG-H5257-sds
ACRO Quality

Part of Bioactivity data

ILG-H52W9-SPR
IL-2 R beta & IL-2 R alpha & IL-2 R gamma SPR

Human IL-2RB&IL-2RA&IL-2RG, His Tag&Twin Strep Tag (Cat. No. ILG-H52W9) captured on CM5 chip via anti-His antibody can bind Human IL-2, Tag Free with an affinity constant of 56.9 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
ILG-H82W9-SPR
IL-2 R beta & IL-2 R alpha & IL-2 R gamma SPR

Biotinylated Human IL-2RB&IL-2RA&IL-2RG, His,Avitag&Twin Strep Tag (Cat. No. ILG-H82W9) captured on Biotin CAP-Series S Sensor Chip can bind Human IL-2 Protein, Tag Free with an affinity constant of 35.1 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

IL-2 R beta & IL-2 R alpha & IL-2 R gamma Molecule Synonym Name

IL-2 R beta & IL-2 R alpha & IL-2 R gamma

IL-2 R beta & IL-2 R alpha & IL-2 R gamma Molecule Background

Both Interleukin-2 receptor subunit beta and Interleukin-2 receptor subunit gamma are receptor for interleukin-2. Common subunit for the receptors for a variety of interleukins. Interacts with SHB upon interleukin stimulation. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit.

IL-2 R beta & IL-2 R alpha & IL-2 R gamma References

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous; Multiple Myeloma Changzhou Pharmaceutical Factory 1982-01-01 HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous; Multiple Myeloma Changzhou Pharmaceutical Factory 1982-01-01 HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Spa Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Spa Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
BNZ-1 BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 Phase 2 Clinical Bioniz Therapeutics Inc Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
umitrelimorgene autodencel ITI-1000 Phase 2 Clinical Immunomic Therapeutics Inc Glioblastoma Details
S-95007 S-95007 Phase 2 Clinical Laboratoires Servier Immune System Diseases; Inflammation Details
AU-007 BD-8; AU-007; BDG-8 Phase 2 Clinical Biolojic Design Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
XTX-202 XTX-202 Phase 2 Clinical Xilio Development Inc, Xilio Therapeutics Inc Solid tumours; Carcinoma, Renal Cell; Melanoma Details
LAT-010 LAT010; LAT-010 Phase 2 Clinical Latticon Antibody Therapeutics Inc Solid tumours Details
COYA-302 COYA302; COYA 302; COYA-302 Phase 2 Clinical Coya Therapeutics Inc Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis Details
AVB-001 AVB-001 Phase 2 Clinical Avenge Bio Inc Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
Saltikva Phase 2 Clinical Salspera LLC Pancreatic Neoplasms Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) Phase 2 Clinical Tcrcure Biopharma Ltd Nasopharyngeal Carcinoma Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital, National Cancer Institute Neuroblastoma Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
SIM-0278 ALM-223; SIM0278 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic Details
Mableukin 2PD1 (Anwita Biosciences) AWT020; AWT-020 Phase 1 Clinical Anwita Biosciences Inc Neoplasms; Autoimmune Diseases of the Nervous System Details
AB-248 AB-248 Phase 1 Clinical Asher Biotherapeutics Inc Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung Details
ASP-1012 VET2-L2; ASP-1012; ASP1012 Phase 1 Clinical KaliVir Immunotherapeutics Inc Solid tumours Details
STK-012 STK-012 Phase 1 Clinical Synthekine Inc Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IL2 CD25 fusion protein (Bristol-Myers Squibb) Phase 1 Clinical University Of Miami Autoimmune Diseases Details
M5A-IL2 Immunocytokine M5A-ICK Phase 1 Clinical National Cancer Institute, City Of Hope National Medical Center Breast Neoplasms; Colorectal Neoplasms Details
DF-6215 DF6215; DF-6215 Phase 1 Clinical Dragonfly Therapeutics Llc Solid tumours Details
Dodekin Phase 1 Clinical Philogen Spa Solid tumours; Neoplasm Metastasis Details
KB-707 KB-707; KB707 Phase 1 Clinical Krystal Biotech Inc Solid tumours; Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
attIL2-T cell therapy Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Soft Tissue Neoplasms; Osteosarcoma; Sarcoma Details
Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) HV-101; HV101 Phase 1 Clinical Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd Solid tumours Details
KY-0118 KY-0118; KY0118 Phase 1 Clinical Novatim Immune Therapeutics (Zhejiang) Co Ltd Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
VIS171 VIS-171; VIS171 Phase 1 Clinical Visterra Inc Autoimmune Diseases Details
MK-1484 MK-1484; SP-482 Phase 1 Clinical Merck & Co Inc, Sutro Biopharma Inc Solid tumours Details
SAR-444336 SAR-444336 Phase 1 Clinical Sanofi Inflammation Details
RS-2102 RS2102 Phase 1 Clinical Reistone Biopharma Co Ltd Dermatitis, Atopic Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
Igrelimogene litadenorepvec PM-1016; PM1016; TILT-123 Phase 1 Clinical Tilt Biotherapeutics Ltd Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Spa Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Spa Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
BNZ-1 BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 Phase 2 Clinical Bioniz Therapeutics Inc Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
umitrelimorgene autodencel ITI-1000 Phase 2 Clinical Immunomic Therapeutics Inc Glioblastoma Details
S-95007 S-95007 Phase 2 Clinical Laboratoires Servier Immune System Diseases; Inflammation Details
AU-007 BD-8; AU-007; BDG-8 Phase 2 Clinical Biolojic Design Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
XTX-202 XTX-202 Phase 2 Clinical Xilio Development Inc, Xilio Therapeutics Inc Solid tumours; Carcinoma, Renal Cell; Melanoma Details
LAT-010 LAT010; LAT-010 Phase 2 Clinical Latticon Antibody Therapeutics Inc Solid tumours Details
COYA-302 COYA302; COYA 302; COYA-302 Phase 2 Clinical Coya Therapeutics Inc Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis Details
AVB-001 AVB-001 Phase 2 Clinical Avenge Bio Inc Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
Saltikva Phase 2 Clinical Salspera LLC Pancreatic Neoplasms Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) Phase 2 Clinical Tcrcure Biopharma Ltd Nasopharyngeal Carcinoma Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital, National Cancer Institute Neuroblastoma Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
SIM-0278 ALM-223; SIM0278 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic Details
Mableukin 2PD1 (Anwita Biosciences) AWT020; AWT-020 Phase 1 Clinical Anwita Biosciences Inc Neoplasms; Autoimmune Diseases of the Nervous System Details
AB-248 AB-248 Phase 1 Clinical Asher Biotherapeutics Inc Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung Details
ASP-1012 VET2-L2; ASP-1012; ASP1012 Phase 1 Clinical KaliVir Immunotherapeutics Inc Solid tumours Details
STK-012 STK-012 Phase 1 Clinical Synthekine Inc Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IL2 CD25 fusion protein (Bristol-Myers Squibb) Phase 1 Clinical University Of Miami Autoimmune Diseases Details
M5A-IL2 Immunocytokine M5A-ICK Phase 1 Clinical National Cancer Institute, City Of Hope National Medical Center Breast Neoplasms; Colorectal Neoplasms Details
DF-6215 DF6215; DF-6215 Phase 1 Clinical Dragonfly Therapeutics Llc Solid tumours Details
Dodekin Phase 1 Clinical Philogen Spa Solid tumours; Neoplasm Metastasis Details
KB-707 KB-707; KB707 Phase 1 Clinical Krystal Biotech Inc Solid tumours; Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
attIL2-T cell therapy Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Soft Tissue Neoplasms; Osteosarcoma; Sarcoma Details
Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) HV-101; HV101 Phase 1 Clinical Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd Solid tumours Details
KY-0118 KY-0118; KY0118 Phase 1 Clinical Novatim Immune Therapeutics (Zhejiang) Co Ltd Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
VIS171 VIS-171; VIS171 Phase 1 Clinical Visterra Inc Autoimmune Diseases Details
MK-1484 MK-1484; SP-482 Phase 1 Clinical Merck & Co Inc, Sutro Biopharma Inc Solid tumours Details
SAR-444336 SAR-444336 Phase 1 Clinical Sanofi Inflammation Details
RS-2102 RS2102 Phase 1 Clinical Reistone Biopharma Co Ltd Dermatitis, Atopic Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
Igrelimogene litadenorepvec PM-1016; PM1016; TILT-123 Phase 1 Clinical Tilt Biotherapeutics Ltd Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap